Effects of CPT‐11 in combination with other anti‐cancer agents in culture
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
CPT‐11, 7‐ethyl‐10‐[4‐( 1 ‐piperidino)‐1 ‐piperidino]carbonyloxy camptothecin, is a newly developed water‐soluble camptothecin derivative now undergoing phase‐II evaluation. In an attempt to establish whether the combination of CPT‐11 with other standard anti‐cancer agents would be of any benefit, we studied the effects of CPT‐11 in combination with 11 other anti‐cancer agents on a human T‐cell leukemia cell line, MOLT‐3, in culture. We used both CPT‐11 and SN‐38 (active substance of CPT‐11 in vivo), for our study. Cells were incubated for 3 days in the presence of 2 drugs (CPT‐11 or SN‐38 and another drug) and cytotoxic effects were determined by MTT assay. The effects of drug combinations on ID 50 were analyzed, by an improved isobologram method. Supra‐additive and marginal supra‐additive effects (synergism) were observed for CPT‐11 in combination with cisplatin, cytosine arabinoside and mitomycin C. Additive effects were observed for its combination with amsacrine, bleomycin, doxorubicin, etoposide, 5‐fluorouracil, mitoxantrone and vincristine. Alternate sub‐additive and protective effects (antagonism) were observed for CPT‐11 in combination with methotrexate. Similar tendencies were observed for SN‐38 in combination with other agents. These results suggest that CPT‐11 in simultaneous administration with a majority of anti‐cancer agents has an advantage for cytokilling. Of these agents, cisplatin, cytosine arabinoside and mitomycin C are most suitable for simultaneous administration with CPT‐11.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)47282-6 · Cited by 887
Cited by
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Pizzolato, J. F., & Saltz, L. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13780-4 · Cited by 359
Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y., & Furukawa, Y. (2001) · Blood · doi:10.1182/blood.v97.7.1999 · Cited by 262
Self-citationTopoisomerase I inhibitors: topotecan and irenotecan
Creemers, G. J., Lund, B., & Verweij, J. (1994) · Cancer Treatment Reviews · doi:10.1016/0305-7372(94)90011-6 · Cited by 252
Recent advances in management of patients with platinum‐refractory testicular germ cell tumors
Kollmannsberger, C., Nichols, C., & Bokemeyer, C. (2006) · Cancer · doi:10.1002/cncr.21742 · Cited by 77
“This was based on a synergistic interaction that had been reported for the combination of irinotecan and cisplatin or nedaplatin in vitro.(53) A very high response rate of 50% was reported for this combination in 20 cisplatin-refractory germ cell cancer patients, which suggested that the synergism of irinotecan with c…”
Background
Metadata
- Authors
- Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Indue, Y., Yosnida, M., Sakamoto, S., & Miura, Y.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1992-02-20
- Volume
- 50
- Issue
- 4
- Pages
- 604-610
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2057331147
- Cited by
- 219
- References
- 1
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of CPT‐11 in combination with other anti‐cancer agents in culture. https://app.cochat.ai/papers/10.1002/ijc.2910500420
- The paper
- Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Indue, Y., Yosnida, M., Sakamoto, S., & Miura, Y. (1992). Effects of CPT‐11 in combination with other anti‐cancer agents in culture. International Journal of Cancer. https://doi.org/10.1002/ijc.2910500420
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.